Asset profile
TML-6
Small molecule
Evidence outlook · lead readout
NCT06562114 · Healthy
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06562114: The study was randomized, double-blind, and placebo-controlled, which is a sound early-phase design, but it only measured safety and pharmacokinetics in healthy and elderly volunteers rather than any disease outcome, and results are not yet posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
April 2028 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.